Drug Topics

DECEMBER 20, 2024

With pressure from the House GOP, expected PBM reform was not included in Congress end-of-year spending package.

Packaging 180

Packaging 180

STAT

DECEMBER 20, 2024

Novo Nordisk’s next-generation obesity candidate led patients to lose a substantial amount of weight in a pivotal study but fell short of expectations, results that cast into doubt the future competitiveness of the company in the booming weight loss market. The treatment, called CagriSema, led patients to lose 20% of their weight at 68 weeks in a late-stage study when looking at all participants, including those who dropped out, Novo said Friday.

111

111

Drug Topics

DECEMBER 20, 2024

Zepbound from Eli Lilly is the first and only prescription medicine approved by the FDA for adults with obstructive sleep apnea and obesity.

FDA 131

FDA 131

Pharmacy Times

DECEMBER 20, 2024

Vanzacaftor/tezacaftor/deutivacaftor (Alyftek) also received approval for the treatment of cystic fibrosis in people 6 years and older who have at least 1 F508del mutation.

FDA 105

FDA 105

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patient Care

Drug Topics

DECEMBER 20, 2024

Recent upticks of the bird flu virus in both dairy cattle and humans have also led to a state of emergency in California.

98

98

The Checkup by Singlecare

DECEMBER 20, 2024

Mixing alcohol with metoprolol can come with various side effects, some of which can be serious. Many people take metoprolol, either as metoprolol tartrate or metoprolol succinate , to help manage high blood pressure and heart conditions. If youre considering drinking alcohol while taking this prescription drug, you should know the possible risks. For some people who know how they react to the medication and alcohol, drinking in moderation may be doable.

Dosage 95

Dosage FDA 95

Fierce Healthcare

DECEMBER 20, 2024

HHS released a list of 64 drugs on Friday that will have reduced co-insurance for patients with Medicare Part B. The discounts come from the Inflation Reduction Act which requires drug makers to give rebates to the federal government when a drug's cost rises more than inflation.

Insurance 80

Insurance 80

STAT

DECEMBER 20, 2024

The Food and Drug Administration on Friday cleared Eli Lilly’s obesity drug Zepbound as the first treatment for a common sleep disorder in the U.S. Zepbound, whose scientific name is tirzepatide, has now been specifically approved for patients with both obesity and moderate-to-severe obstructive sleep apnea, or OSA, a condition characterized by breathing interruptions during sleep.

Insurance Coverage 121

Insurance Coverage Insurance 121

Drug Topics

DECEMBER 20, 2024

Although the drug fell short of its 25% expected weight loss, results are still promising for people with overweight or obesity.

76

76

Fierce Pharma

DECEMBER 20, 2024

Perhaps PD-1 inhibitors just arent for ovarian cancer after all. | Merck's and GSK's similar overall survival setbacks suggest that PD-1 inhibitors may not be for ovarian cancer after all.

74

74

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

Pharmacy Times

DECEMBER 20, 2024

The new approval continues to expand the therapeutic potential of GLP-1 medications such as tirzepatide, now being deemed effective in patients with obstructive sleep apnea.

FDA 73

FDA 73

Fierce Pharma

DECEMBER 20, 2024

Merck in-licensed a preclinical oral GLP-1 candidate from China's Hansoh Pharma. Astellas doubled down in gene therapy with a viral capsid deal with Sangamo Therapeutics. Betta Pharma's Ensacove became the first innovative targeted lung cancer med developed by a Chinese company to win FDA approval. And more.

FDA 69

FDA 69

Pharmacy Times

DECEMBER 20, 2024

Varicella-zoster vaccination could prevent fatal outcome among individuals with disseminated herpes zoster.

Vaccines 73

Vaccines 73

Pharmaceutical Technology

DECEMBER 20, 2024

Novo Nordisk has announced positive results from its Phase III trial of CagriSema but fell short of a previously promised 25% weight loss.

64

64

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

Pharmacy Times

DECEMBER 20, 2024

The approval follows positive results from the V005 (NCT03005418) clinical trial.

FDA 73

FDA 73

Pharmaceutical Technology

DECEMBER 20, 2024

The US Food and Drug Administration (FDA) has stood by an earlier decision confirming that the tirzepatide shortage is over.

FDA 64

FDA 64

Pharmacy Times

DECEMBER 20, 2024

Compounding pharmacies have a 60- to 90-day grace period to complete production as it continues to monitor supply and demand.

Compounding 73

Compounding Compounding Pharmacies FDA 73

Pharmaceutical Technology

DECEMBER 20, 2024

Astellas Pharma and Sangamo have signed a licence agreement for neurotropic adeno-associated virus (AAV) capsid, STAC-BBB.

64

64

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

Pharmacy Times

DECEMBER 20, 2024

Pharmacists identify appropriate patients for new oral and antibody drug conjugate treatments and provide counseling to help patients navigate the evolving treatment landscape.

65

65

STAT

DECEMBER 20, 2024

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is still shaping up, but we do foresee a few developments, such as promenading the official mascots, hanging with one of our short people, and escorting Mrs. Pharmalot to a house party or two.

Compounding 69

Compounding FDA 69

Pharmacy Times

DECEMBER 20, 2024

The decision is based off favorable results from the BREAKWATER trial.

65

65

Fierce Pharma

DECEMBER 20, 2024

Thanks to a new FDA green light, Lillys dual GIP/GLP-1 blockbuster Zepbound has become the first prescription medicine cleared to treat adults with moderate-to-severe obstructive sleep apnea and obesity. The nod marks the second indication for Zepbound behind the inaugural obesity approval it scored in November 2023.

FDA 60

FDA 60

Pharmacy Times

DECEMBER 20, 2024

Setmelanotide is indicated to reduce excess body weight and maintain weight reduction long-term for patients with syndromic or monogenic obesity due to Bardet-Biedl syndrome.

FDA 65

FDA 65

Pharmaceutical Technology

DECEMBER 20, 2024

The US FDA has approved Ionis' TRYNGOLZA (olezarsen) as an adjunct to diet for reducing triglyceride levels in the adult population with FCS

FDA 59

FDA 59

Pharmacy Times

DECEMBER 20, 2024

Compounding pharmacies play a vital role in meeting the unique needs of patients, but pharmacists must adhere to strict safety standards and regulations.

Compounding 65

Compounding Compounding Pharmacies 65

Fierce Healthcare

DECEMBER 20, 2024

Smart ring maker Oura pocketed an additional $125 million following a $75 million investment from medical device maker Dexcom last month. | Smart ring maker Oura pocketed an additional $125 million following a $75 million investment from medical device maker Dexcom last month.

59

59

Pharmacy Times

DECEMBER 20, 2024

Knowing which patients are at higher risk for developing urticaria by analyzing their history of food allergies could lead to better outcomes in this population.

65

65

PharmaVoice

DECEMBER 20, 2024

The high drama of an election year, industry layoffs, patent cliff strategies and other key trends that shaped pharma in 2024.

59

59

Pharmacy Times

DECEMBER 20, 2024

The rare genetic disease is a severe hypertriglyceridemia that can lead to potentially life-threatening acute pancreatitis.

FDA 65

FDA 65

Pharmaceutical Technology

DECEMBER 20, 2024

Palleon and Henlius Biotech have entered into a licence agreement and partnership for the formers E-602 to treat autoimmune diseases.

59

59

Pharmacy Times

DECEMBER 20, 2024

The findings show a need for researchers and health care professionals to consider model designs to minimize disparities when diagnosing perinatal mood and anxiety disorders (PMADs).

65

65

Pharmaceutical Technology

DECEMBER 20, 2024

The UK's DHSC has announced its anticipated 2025 headline payback rate for new medicines under the 20242028 VPAG.

59

59

Pharmacy Times

DECEMBER 20, 2024

Traci M. Poole, PharmD, BCACP, BCGP, discusses the pathophysiology of respiratory syncytial virus (RSV) and its key complications, identifies high-risk populations for severe RSV infection, and explores best practices for recognizing these patients and ensuring they receive timely vaccination to prevent serious outcomes.

Vaccines 65

Vaccines 65